Use of amiodarone in emergency

European Review for Medical and Pharmacological Sciences

Volumn 9, Issue 3, 2005, Pages 183-190

  Testa, A ^a   Ojetti, V ^a   Migneco, A ^a   Serra, M ^a   Ancona, C ^a   De Lorenzo, A ^b   Gentiloni Silveri, N ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Amiodarone; Arrhythmias; Atrial fibrillation; Cardiac arrest; Emergency; Tachycardias; Ventricular tachycardia

Indexed keywords

AMIODARONE; ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTITHYROID AGENT; CYCLOSPORIN; DIGITALIS; DIGOXIN; DISOPYRAMIDE; DIURETIC AGENT; DOFETILIDE; ERYTHROMYCIN; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PENTAMIDINE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; QUINOLONE DERIVATIVE; SILDENAFIL; SIMVASTATIN; SOTALOL; SULTOPRIDE; THYROID HORMONE; VINCAMINE; WARFARIN;

ANOREXIA; ATRIOVENTRICULAR BLOCK; BODY WEIGHT DISORDER; BRADYCARDIA; CARDIOVERSION; CENTRAL VENOUS CATHETERIZATION; CLINICAL TRIAL; COUGHING; DISEASE CONTROL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG TISSUE LEVEL; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; EMERGENCY TREATMENT; FEVER; GENERAL ANESTHESIA; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE FAILURE; HEART SINOATRIAL BLOCK; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HEMOPTYSIS; HUMAN; HYPERTHYROIDISM; HYPOTENSION; HYPOTHYROIDISM; LIVER FAILURE; LIVER TOXICITY; MAINTENANCE DRUG DOSE; META ANALYSIS; MYOPATHY; NAUSEA; OPTIC NERVE DISEASE; PHARMACODYNAMICS; PHLEBITIS; PHOTOSENSITIVITY; QT PROLONGATION; RESPIRATORY FAILURE; RESUSCITATION; REVIEW; SKIN DISCOLORATION; SYSTEMATIC REVIEW; THORAX PAIN; TORSADE DES POINTES;

AMIODARONE; DRUG INTERACTIONS; EMERGENCIES; HEART ARREST; HUMANS; TACHYCARDIA;

EID: 22144483746     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Letelier LM, Udol K, Ena J, Weaver B, Guyatt GH. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis. Arch Intern Med 2003; 163: 777-785.
2. Caron MF, Kluger J, White CM. Amiodarone in the new AHA guidelines for ventricular tachyarrhythmias. Ann Pharmacother 2001; 35: 1248-1254.
3. No authors listed. Part 6: advanced cardiovascular life support. Section 7: algorithm approach to ACLS emergencies. 7d: the tachycardia algorithms. European Resuscitation Council. Resuscitation 2000; 23;46(1-3): 185-193.
4. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or ripetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997; 349: 675-682.
5. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction. EMIAT. European Myocardial Infarctions Amiodarone Trial Investigators. Lancet 1997; 349: 667-674.
6. Cottino A, Ferraudo G, Germena C, et al. Aritmie ipercinetiche parossistiche: 836 casi. Cenni di epidemiologia. Atti del IV Congresso Nazionale dell'associazione Nazionale dei Medici d'Urgenza. Monduzzi Ed - Bologna 1989; p. 427.
7. Rizzon P, Biasco G, di Biase M, Antonelli G. Anti-anginal and anti-arrhythmic properties of amiodarone. Boll Soc Ital Cardiol 1972; 17: 413-417.
8. Polster P, Broekhuisen J. The adrenergic antagonism of amiodarone. Biochem Pharmacol 1976; 25: 131-136.
9. Goupil N, Lenfant J. The effect of amiodarone on the sinus node activity of the rabbit heart. Eur J Pharmacol 1976; 39: 23-26.
10. Rosenbaum MB, Chiale PA, Halpern MS, et al. Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol 1976; 38: 934-944.
11. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev 2001; 22: 240-254.
12. Patterson E, Walden KM, Khazaeli MB, Montgomery DG, Lucchesi BR. Cardiac electrophysiologic effects of acute and chronic amiodarone administration in the isolated perfused rabbit heart: altered thyroid hormone metabolism. J Pharmacol Exp Ther 1986; 239: 179-184.
13. Yin Y, Vassy R, Nicolas P, Perret GY, Laurent S. Antagonism between T3 and amiodarone on the contractility and the density of beta-adrenoceptor on chicken cardiac myocytes. Eur J Pharmacol 1994; 261: 97-104
14. Forini F, Nicolini G, Balzan S, et al. Amiodarone inhibits the 3,5,3′-triiodothyronine-dependent increase of sodium/potassium adenosine triphosphatase activity and concentration in human atrial myocardial tissue. Thyroid 2004; 14: 493-499.
15. Drvota V, Carlsson B, Haggblad J, Sylven C. Amiodarone is a dose-dependent noncompetitive and competitive inhibitor of T3 binding to thyroid hormone receptor subtype beta 1, whereas disopyramide, lignocaine, propafenone, metoprolol, dl-sotalol, and verapamil have no inhibitory effect. J Cardiovasc Pharm 1995; 26: 222-226.
16. Kennedy RI, Griffiths H, Gray TA. Amiodarone and the thyroid. Clin Chem 1989; 35: 1882-1887.
17. Huang O, Geller HM, Green WL, et al. Acute effects of thyroid hormone analog on sodium currents in neonatal rat myocytes. J Mol Cell Cardiol 1999; 31: 881-893.
18. Kodama I, Kamiya K, Toyama J. Amiodarone: ionic and cellular mechanism of action of the most promising class III agent. Am J Cardiol 1999; 84: 20R-28R.
19. Maltsev VA, Sabbah HN, Undrovinas AI. Late sodium current is a novel target for amiodarone: studies in failing human myocardium. J Mol Cell Cardiol 2001; 33: 923-932.
20. Kamiya K, Nishiyama A, Yasui K, Hojo M, Sanguinetti MC, Kodama I. Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current. Circulation 2001; 103: 1317-1324.
21. Holt DW, Tucker Gt, Jackson PR, Storey GC. Amiodarone pharmacokinetics. Am Heart J 1983; 106: 840-847.
22. Broekhuysen J, Larvel L, Sion R. Recherches dans la serie des benzofuranes. Arch Int Pharmacodyn 1969;177: 348.
23. Bongiorni MG. Amiodarone: effetti collaterali. Ital Heart J 2001; 2: 475-525.
24. The American Heart Association in Collaboration with the International Liaison Committee on Resuscitation (ILCOR). Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care-an International Consensus on Science. Resuscitation 2000; 46: 1-448
25. The 1998 European Resuscitation Council Guidelines for Adult Advanced Life Support. In: Bossaert L (ed.). European Resuscitation Council Guidelines for Resuscitation. Amsterdam: Elsevier, 1998; 36-47
26. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 1999; 341: 871-878
27. Deharo JC, Mouliom F, Salamand A, Djiane P. Role of antiarrhythmic drugs in reducing the number of defibrillation shocks. Arch Mal Coeur Vaiss 2005; 98: 140-144
28. European Resuscitation Council Guidelines 2000 for Adult Advanced Life Support. A statement from the Advanced Life Support Working Group (1) and approved by the Executive Committee of the European Resuscitation Council. Resuscitation 2001; 48: 211-221.
29. Trappe HJ, Brandts B, Weismueller P. Arrhythmias in the intensive care patient. Curr Opin Crit Care 2003; 9: 345-355.
30. Levine JH, Massumi A, Scheinman MM, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol 1996; 27: 67-75.
31. Domanovits H, Paulis M, Nikfardjam M, et al. Sustained ventricular tachycardia in the emergency department. Resuscitation 1999; 42: 19-25.
32. Kuga K, Yamaguchi I, Sugishita Y. Effect of intravenous amiodarone on electrophysiologic variables and on the modes of termination of atrioventricular reciprocating tachycardia in Wolff-Parkinson-White syndrome. Jpn Circ J 1999; 63: 189-195.
33. Kowey PT, Levine JH, Herre JM, et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995; 92: 3255-3263.
34. Kerin NZ, Faitel K, Naini M. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation: amiodarone vs quinidine for conversion of atrial fibrillation. Arch Intern Med 1996; 156: 49-53.
35. Horner SM. A comparison of cardioversion of atrial fibrillation using oral amiodarone, intravenous amiodarone and DC cardioversion: Acta Cardiol 1992; 47: 473-480.
36. Singh Bn, Singh Sn, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352: 1861-1872.
37. Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P. Amiodarone versus placebo and classic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2003; 41: 255-262.
38. Zahir S, Lheureux P. Management of new-onset atrial fibrillation in the emergency department: is there any predictive factor for early successful cardioversion? Eur J Emerg Med 2005; 12: 52-56.
39. Boriani G, Diemberger I, Biffi M, Martignani C, Branzi A. Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs 2004; 64: 2741-2762.
40. Bartlett TG, Friedman PL. Current management of the Wolff-Parkinson-White syndrome. J Card Surg 1993; 8: 503-515.
41. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30: 791-798.
42. Somberg JC, Cvetanovic I, Ranade V, Molnar J. Comparative effects of rapid bolus administration of aqueous amiodarone versus 10-minute cordarone I.V. infusion on mean arterial blood pressure in conscious dogs. Cardiovasc Drugs Ther 2004; 18: 345-351.
43. Pollak PT. Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations. Am J Cardiol 1999; 84: 37-45.
44. Iervasi G, Clerico A, Bonini R, et al. Acute effects of amiodarone administration on thyroid function in patients with cardiac arrhythmias. J Clin Endocrinol Metab 1997; 82: 275-280.
45. Bravo AE, Drewe J, Schlienger RG, Krahenbuhl S, Pargger H, Ummenhofer W. Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature. Crit Care Med 2005; 33: 128-134.
46. Roten L, Schoenenberger Ra, Krahenbuhl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 2004; 38: 978-981.
47. Yamreudeewong W, Debisschop M, Martin LG, Lower DL. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 2003; 26: 421-438.
48. Latini R. Tognoni G, Kates RE. Clinical pharmakinetics of amiodarone. Clin Pharmacokinet 1984; 9: 136-156.
49. Moysey Jo, Jaggarao Nsv, Grundy En, Chamberlain DA. Amiodarone increases plasma digoxin concentrations. Brit Med J 1981; 282: 272-275.
50. Chitwood KK, Abdul-Haqq AJ, Heim-Duthoy KL. Cyclosporine-amiodarone interaction. Ann Pharmacother 1993: 569-571.
51. Donaldson L, Grant IS, Naysmith MR, Thomas JS. Acute amiodarone-induced lung toxicity. Intensive Care Med 1998; 24: 626-630.